No Data
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Delivers Shareholders Stellar 23% CAGR Over 5 Years, Surging 4.7% in the Last Week Alone
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks